<unk>  is the sodium-salt form of (S)-2-(diphenylacetyl)-l,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)- 3-isoquinoline carboxylic acid.<unk>  dose of up to 400 mg was tested in healthy male adults without any major adverse effects.<unk>  has been administered orally at a standardized dose of 100 mg twice daily.<unk>  reaches a maximum plasma concentration of 1000 ug/L one-hour after administration of 100 mg of<unk>  in both men and women, as observed in a phase II trial.<unk>  has an elimination half-life of 6 hours on day 1 of drug intake increasing to 12 hours by day seven of drug intake. Total plasma concentration of<unk>  is consistent over 28 days. A steady state of minimum drug plasma concentration is reached by the 8th day of being on the drug.<unk>  does not accumulate in the blood at presently administered doses.<unk>  does not cross the blood-brain barrier, therefore has little effect on the central nervous system.
EMA401
MRK-016
AEMT-CC
OSU-6162
ICE 
HAMLET 
ZF2001
DEBRA